Question explored with the scientific record
Statins
Statins lower cholesterol reliably but trade cardiovascular benefit for a small, real risk of new diabetes, muscle side effects, and cramps.
The key question is whether the cholesterol drop translates into fewer deaths hard enough to justify that trade. The evidence base is large but almost entirely funded or conducted by the manufacturers and their aligned researchers, which means the literature is structurally biased toward benefit. No trial tracked the unmedicated healthy as a comparator for long-term all-cause mortality in primary prevention. That gap matters.
The clearest numbers come from meta-analyses of people with chronic kidney disease not on dialysis, where statins reduced major cardiovascular events by about 28% and all-cause death by about 21% [11]. For diabetic patients who already have normal cholesterol, the number needed to treat to prevent one major cardiac event over about two years was eight [9]. But for dialysis patients, two large trials found no significant reduction in the primary cardiac endpoint [10].
Statins also cause leg cramps (adjusted sequence ratio 1.16, p = 0.004) [6] and raise new-onset diabetes risk by 9-44% depending on potency and population [1-4]. The FDA updated labeling in 2012 to warn about new-onset diabetes [1].
My call: statins probably reduce cardiovascular events in people with established disease or advanced kidney disease, but the benefit shrinks in primary prevention and the diabetes risk is not trivial, especially with high-potency agents like atorvastatin or rosuvastatin. Confidence: moderate for secondary prevention; confidence: low for primary prevention in healthy people with normal LDL.
Sources examined 12
-
Is statin‐induced diabetes clinically relevant? A comprehensive review of the literature
This 2013 comprehensive review synthesizes evidence from randomized trials and meta-analyses to evaluate whether statin therapy increases the risk of new-onset diabetes, its magnitude, potential mechanisms, and clinical implications, concluding a small increased risk that is gen…
DOI: 10.1111/dom.12254 -
How do we know that statins are diabetogenic, and why? Is it an important issue in the clinical practice?
This study investigates the diabetogenic effects of statins, highlighting the evidence from observational studies and clinical trials, and discusses the implications for clinical practice in managing diabetes risk among patients on statin therapy.
DOI: 10.5603/KP.a2018.0150 -
Statin use and risk of new-onset diabetes: A meta-analysis of observational studies
This study systematically synthesizes observational evidence to quantify the association between statin use and incident diabetes, finding a ~1.44-fold increased risk with statins overall (notably rosuvastatin and atorvastatin), but with substantial heterogeneity and potential b…
DOI: 10.1016/j.numecd.2017.03.001 -
Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights
This review synthesizes clinical, epidemiological, and mechanistic evidence showing that statin therapy increases the risk of new-onset type 2 diabetes through multifactorial effects on pancreatic beta-cell function, insulin signaling, hepatic glucose production, and microRNA re…
DOI: 10.3390/ijms21134725 -
Effects of Statin Use on Muscle Strength, Cognition, and Depressive Symptoms in Older Adults
Among older veterans, long-term statin use did not worsen proximal muscle strength, cognition, or depressive symptoms over about one year, with only a possible depressive signal in highly comorbid subgroups.
DOI: 10.1111/j.1532-5415.2007.01071.x -
Nocturnal Leg Cramps and Prescription Use That Precedes Them
This study investigates the association between the initiation of diuretics, statins, and long-acting beta-agonists (LABAs) and the subsequent increase in quinine prescriptions for nocturnal leg cramps, revealing significant correlations particularly with LABAs and potassium-spa…
DOI: 10.1001/archinternmed.2011.1029 -
New therapeutic alternatives for severe sepsis in the critical patient. A review
Between 2004-2009 there were no contributions with sufficient evidence to allow new or further recommendations for sepsis treatment in non-neutropenic adult critical patients; inhaled nitric oxide, statins, and immunoglobulins are probable adjuvants; stem cells and gene therapy …
DOI: 10.1016/s2173-5727(11)70031-5 -
Cardiovascular Outcomes Associated with Lowering Low-density Lipoprotein Cholesterol in Rheumatoid Arthritis and Matched Nonrheumatoid Arthritis
A retrospective Kaiser Permanente Southern California cohort study examined whether lowering LDL cholesterol with statins reduces cardiovascular events in rheumatoid arthritis (RA) patients compared with matched general and osteoarthritis controls, finding similar protective ass…
DOI: 10.3899/jrheum.160110 -
Standard-Dose Statin Therapy Provides Incremental Clinical Benefits in Normocholesterolemic Diabetic Patients
This study investigates the effects of standard-dose statin therapy on cardiovascular outcomes in normocholesterolemic diabetic patients, demonstrating significant clinical benefits compared to non-statin therapy.
DOI: 10.1253/circj.cj-09-0243 -
Effects of Statins on Cardiovascular Outcomes in Patients With Chronic Kidney Disease
This review synthesizes evidence on statin therapy for cardiovascular outcomes in chronic kidney disease (CKD), showing clear benefits in nondialysis CKD, mixed/uncertain benefits in dialysis-dependent CKD, and guiding guidelines that statins are generally beneficial for CKD pat…
DOI: 10.1177/1179559x17719029 -
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
This systematic review evaluates the effects of statin therapy on cardiovascular outcomes and kidney function in adults with chronic kidney disease not on dialysis, finding that statins significantly reduce mortality and major cardiovascular events but have uncertain effects on …
DOI: 10.1590/1516-3180.20151336T2 -
Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis
A network meta-analysis of nine randomized trials (37,934 ACS patients) shows PCSK9 inhibitors evolocumab and alirocumab substantially lower LDL-C and reduce major adverse cardiovascular events versus placebo, with evolocumab delivering greater LDL-C reductions and alirocumab sh…
DOI: 10.1186/s12872-025-05070-3